TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration (VERTACL)
Multi-Center, Randomized, Phase II Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide and Avastin® in Combination With Photodynamic Therapy in Participants With Neovascular Age Related Macular Degeneration
Sponsor: National Eye Institute (NEI)
Terminated
Study was terminated because of poor enrollment.
Other terminated trials from National Eye Institute (NEI)
Other Age-Related Macular Degeneration trials with similar outcome
A PHASE2 clinical study on Age-Related Macular Degeneration, this trial is terminated or withdrawn. The trial is conducted by National Eye Institute (NEI) and has accumulated 6 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Eye Institute (NEI)
- QLT Inc.
For direct contact, visit the study record on ClinicalTrials.gov .